The Charlson comorbidity index is a prognostic factor in sinonasal tract squamous cell carcinoma.

OBJECTIVE High Charlson comorbidity index values have been reported to be associated with shorter overall survival in various types of cancer. We investigated whether Charlson comorbidity index values were correlated with overall survival in patients with resectable sinonasal tract squamous cell carcinoma. METHODS Seventy-nine patients with resectable sinonasal tract squamous cell carcinoma were treated with curative intent. The Charlson comorbidity index values were calculated by the summation of the weight scores of 19 medical conditions (other than sinonasal tract squamous cell carcinoma) before treatment. The survival rate was analyzed according to the Kaplan-Meier method. Univariate and multivariate survival analyses were performed using the Wilcoxon test and the Cox proportional hazards model, respectively. RESULTS According to a univariate analysis, a Charlson comorbidity index value ≥6 was found to be significantly correlated with shorter overall survival (P < 0.02). In the multivariate survival analysis with adjustment for the clinical T and N classification, age, sex, anatomical location, treatment group (radiotherapy/surgery) and chemotherapy (presence/absence), a Charlson comorbidity index value ≥6 was found to be associated with the significantly shorter overall survival. CONCLUSIONS These results suggest that the Charlson comorbidity index functions as a prognostic factor in cases of resectable sinonasal tract squamous cell carcinoma.

[1]  R. Gilbert,et al.  Comorbidity and performance status as independent prognostic factors in patients with head and neck squamous cell carcinoma , 2016, Head & neck.

[2]  J. Eloy,et al.  Squamous cell carcinoma of the maxillary sinus: A population‐based analysis , 2016, The Laryngoscope.

[3]  J. Waldron,et al.  Comorbidity and prognosis in head and neck cancers: Differences by subsite, stage, and human papillomavirus status , 2014, Head & neck.

[4]  S. Naganawa,et al.  Prognostic value of 18F-fluorodeoxyglucose uptake before treatment for pharyngeal cancer , 2014, Annals of Nuclear Medicine.

[5]  J. Overgaard,et al.  Evaluation of comorbidity in 9388 head and neck cancer patients: a national cohort study from the DAHANCA database. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  J. Roh,et al.  Prognostic value of total tumor volume in advanced‐stage laryngeal and hypopharyngeal carcinoma , 2013, Journal of surgical oncology.

[7]  F. Khuri,et al.  Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009 , 2013, Cancer.

[8]  M. Beland,et al.  Charlson Comorbidity Index predicts patient outcome, in cases of inoperable non-small cell lung cancer treated with radiofrequency ablation. , 2012, European journal of radiology.

[9]  S. Naganawa,et al.  Treatment outcomes of definitive chemoradiotherapy for patients with hypopharyngeal cancer , 2012, Journal of radiation research.

[10]  A. Parwani.  Human Papillomaviruses Are Identified in a Subgroup of Sinonasal Squamous Cell Carcinomas With Favorable Outcome , 2010 .

[11]  Tatsuya Nakamura,et al.  Treatment results of continuous intra-arterial CBDCA infusion chemotherapy in combination with radiation therapy for locally advanced tongue cancer. , 2008, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[12]  Kiyoshi Saito,et al.  En bloc petrosectomy for malignant tumors involving the external auditory canal and middle ear: surgical methods and long-term outcome. , 2008, Journal of neurosurgery.

[13]  G. Pond,et al.  Prognostic factors for life expectancy in nonagenarians with nonmelanoma skin cancer: implications for selecting surgical candidates. , 2002, Journal of the American Academy of Dermatology.

[14]  C. Snyderman,et al.  Squamous Cell Carcinoma of the Sinonasal Tract Invading the Orbit , 1999, The Laryngoscope.

[15]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[16]  J. Batsakis,et al.  The pathology of head and neck tumors: squamous and mucous-gland carcinomas of the nasal cavity, paranasal sinuses, and larynx, part 6. , 1980, Head & neck surgery.